top of page
Not compatible with Internet Explorer
Not compatible with Internet Explorer
Not compatible with Internet Explorer
Search
Kadimastem Expands R&D Program to Include Multiple Sclerosis
Following positive results from its first clinical study in ALS, Kadimastem Tests The Potential of AstroRx® As A Therapeutic Treatment...
May 17, 20224 min read
Kadimastem Receives Grant for a Total Budget of $3.1 million from the Israeli Innovation Authority
The Grant will support the Further Development of Cell Therapy Product AstroRx®, for the Treatment of ALS And support the Company’s FDA...
Mar 3, 20223 min read
Kadimastem Announces the Approval of a 4M NIS ($1.29M) Budget from the Israel Innovation Authority
For the Support of Production Scale Up of Astrocyte cells Used to Produce ALS Cell Therapy Treatment AstroRx® in Preparation for Phase...
Dec 13, 20214 min read
ILEX Medical to Invest 10 million NIS ($3.2 million)
ILEX Medical receives options that if exercised would increase this financing round to 21 million NIS ($6.7 million) Kadimastem's Board...
Nov 25, 20215 min read
We rang the TASE bell today!
In honor of the “International Diabetes Awareness Day” and the 100-year anniversary of the discovery of insulin, Kadimastem opened the...
Nov 15, 20211 min read
Kadimastem Raises NIS 16.1 million ($5 million) In Private Placement
The raise was led by Clover Wolf, Alpha Capital Anstalt and the controlling shareholders of the company, Professor Michel Revel and Mr....
Oct 25, 20214 min read
Successful Meeting with the FDA (INTERACT) Regarding IsletRx for the Treatment of Diabetes
Kadimastem Holds Successful Preliminary Meeting with the FDA (INTERACT) Regarding IsletRx for the Treatment of Diabetes NESS ZIONA,...
Oct 12, 20213 min read
Patent for Cell Selection of Beta Cells to Treat and Potentially Cure Diabetes was Granted in Japan
Ness Ziona, Israel, July, 2021 --- Cell therapy company Kadimastem Ltd (TASE: KDST) has received its patent approval from the Japanese...
Jul 21, 20213 min read
Kadimastem Announces Publication in Frontiers in Endocrinology of a Peer-Reviewed Article
Demonstrating Advancement in the Company’s Technology to Treat Diabetes Ness Ziona, Israel, May 11th, 2021, Kadimastem (TASE: KDST), a...
May 11, 20213 min read
Kadimastem Raises NIS 22.3 Million ($6.8 Million)
Total Potential of NIS 53.4 Million ($16 Million) with Warrants in a Private Placement Institutional investors Alpha Capital Anstalt and...
Apr 26, 20213 min read
Kadimastem Granted a Patent in Israel for the Treatment of ALS
Kadimastem Granted a Patent in Israel for the Directed Differentiation of Astrocytes from Human Pluripotent Stem Cells (AstroRx®) for use...
Mar 9, 20213 min read
Kadimastem Announces Executive Management Changes
Accomplished US Life Science and Biotech Executive Asaf Shiloni Named New CEO Company Appoints Biotech Industry Leaders Ronen Twito, CPA...
Jan 31, 20215 min read
Encouraging Results of Cohort B of its Phase 1/2a Clinical Trial of AstroRx® for ALS
No treatment-related serious adverse events nor dose-limiting toxicities were reported during the 6- month post-treatment follow up...
Dec 15, 20205 min read
Kadimastem Reports Positive Interim Results of Cohort B of its AstroRx® Phase 1/2a Clinical Trial in
AstroRx® demonstrated to be safe and well tolerated in the higher treatment dose Clinically meaningful decline in disease progression...
Aug 3, 20207 min read
Kadimastem Announces Promising Results of Cohort A of its Phase 1/2a Clinical Trial in ALS
No treatment-related serious adverse events nor dose-limiting toxicities were reported A statistically significant decline in disease...
Jan 2, 20207 min read
Kadimastem Announces the Completion of Treatment for Cohort B
The patients in this Cohort were treated with a single dose of 250x106 cells of AstroRx® The clinical trial continues as planned. Cohort...
Dec 23, 20194 min read
Successful Preclinical results of our Cell Therapy Treatment for Insulin-Dependent Diabetes
Study results demonstrate IsletRx cells ability to balance blood sugar levels and maintain normal levels over time Unique technology...
Nov 19, 20194 min read
Kadimastem to Submit an Amendment of its ALS Phase 1/2a Clinical Trial Protocol
Following Recent Positive Interim Results The Company intends to assess the safety and efficacy of a repeated administration of the low...
Nov 17, 20194 min read
Kadimastem to Present at the 7th International Stem Cell Meeting, in Tel-Aviv
Kadimastem to Present Interim Results of Cohort A of its Phase 1/2a Clinical Trial in ALS at the 7th International Stem Cell Meeting, in...
Nov 11, 20193 min read
Kadimastem Announces Promising Interim Results of Cohort A of its Phase 1/2a Clinical Trial in ALS
Disease progression was reduced in the first 3 months post-treatment period compared to the 3 months pre-treatment period, this...
Sep 24, 20195 min read
bottom of page